应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INBX Inhibrx Biosciences
未开盘 11-17 16:00:00 EST
74.18
-3.48
-4.48%
盘后
76.50
+2.32
+3.13%
19:30 EST
最高
78.21
最低
72.83
成交量
30.03万
今开
78.21
昨收
77.66
日振幅
6.93%
总市值
10.96亿
流通市值
6.37亿
总股本
1,477万
成交额
2,226万
换手率
3.50%
流通股本
858.89万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Inhibrx Biosciences公布实验性联合抗癌药中期研究数据后,股价重挫22%
美股速递 · 09-08
Inhibrx Biosciences公布实验性联合抗癌药中期研究数据后,股价重挫22%
Inhibrx Biosciences:INBRX-106围手术期非小细胞肺癌Ⅰ/Ⅱ期临床试验进行中,初步结果预计2027年年中公布
美股速递 · 09-08
Inhibrx Biosciences:INBRX-106围手术期非小细胞肺癌Ⅰ/Ⅱ期临床试验进行中,初步结果预计2027年年中公布
Inhibrx Biosciences:拟探索Inbrx-106与治疗性癌症疫苗联合应用的潜力
美股速递 · 09-08
Inhibrx Biosciences:拟探索Inbrx-106与治疗性癌症疫苗联合应用的潜力
Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中:缓解率近乎翻倍,无进展生存期中位数达9.6个月
美股速递 · 09-08
Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中:缓解率近乎翻倍,无进展生存期中位数达9.6个月
H.c. Wainwright首次覆盖Inhibrx Biosciences,给予买入评级及245美元目标价
美股速递 · 08-24
H.c. Wainwright首次覆盖Inhibrx Biosciences,给予买入评级及245美元目标价
Inhibrx Biosciences二次修订协议带来总计3.25亿美元资金,含1亿美元已到位与2.25亿美元可用额度
美股速递 · 07-16
Inhibrx Biosciences二次修订协议带来总计3.25亿美元资金,含1亿美元已到位与2.25亿美元可用额度
Inhibrx宣布与牛津金融修订贷款协议,总授信额度增至5亿美元
美股速递 · 07-16
Inhibrx宣布与牛津金融修订贷款协议,总授信额度增至5亿美元
Inhibrx宣布美国FDA受理Ozekibart用于治疗常规软骨肉瘤患者的生物制品许可申请
美股速递 · 06-15
Inhibrx宣布美国FDA受理Ozekibart用于治疗常规软骨肉瘤患者的生物制品许可申请
Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%
市场透视 · 2025-03-06
Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%
Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%
市场透视 · 2025-03-04
Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%
Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%
市场透视 · 2025-03-01
Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%
Inhibrx Biosciences, Inc.盘中异动 股价大涨12.34%
市场透视 · 2025-02-21
Inhibrx Biosciences, Inc.盘中异动 股价大涨12.34%
Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.19%
市场透视 · 2025-02-06
Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.19%
Inhibrx Biosciences, Inc.盘中异动 急速下挫5.23%报12.87美元
市场透视 · 2025-02-03
Inhibrx Biosciences, Inc.盘中异动 急速下挫5.23%报12.87美元
Inhibrx Biosciences, Inc.盘中异动 早盘急速上涨5.77%
市场透视 · 2025-01-30
Inhibrx Biosciences, Inc.盘中异动 早盘急速上涨5.77%
Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元
市场透视 · 2025-01-27
Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元
Inhibrx Biosciences, Inc.盘中异动 大幅下挫5.22%
市场透视 · 2025-01-24
Inhibrx Biosciences, Inc.盘中异动 大幅下挫5.22%
Inhibrx Biosciences, Inc.盘中异动 股价大涨5.40%报14.22美元
市场透视 · 2025-01-21
Inhibrx Biosciences, Inc.盘中异动 股价大涨5.40%报14.22美元
Inhibrx Biosciences, Inc.盘中异动 股价大涨6.90%
市场透视 · 2025-01-16
Inhibrx Biosciences, Inc.盘中异动 股价大涨6.90%
Inhibrx Biosciences, Inc.盘中异动 急速拉升8.08%
市场透视 · 2025-01-15
Inhibrx Biosciences, Inc.盘中异动 急速拉升8.08%
公司概况
公司名称:
Inhibrx Biosciences
所属市场:
NASDAQ
上市日期:
--
主营业务:
Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立,是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司,拥有一系列新型候选生物治疗药物,使用其专有的模块化蛋白质工程平台开发。
发行价格:
--
{"stockData":{"symbol":"INBX","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences","latestPrice":74.18,"timestamp":1794949200000,"preClose":77.66,"halted":0,"volume":300269,"hourTrading":{"tag":"盘后","latestPrice":76.5,"preClose":74.18,"latestTime":"19:30 EST","volume":224,"amount":16939.83,"timestamp":1794961801921,"change":2.32,"changeRate":0.031275,"amplitude":0.031275},"delay":0,"changeRate":-0.044810713365954026,"floatShares":8588900,"shares":14769076,"eps":-9.064806,"marketStatus":"未开盘","change":-3.48,"latestTime":"11-17 16:00:00 EST","open":78.21,"high":78.21,"low":72.83,"amount":22261736.47439,"amplitude":0.069276,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.064806,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794992400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":77.66,"postHourTrading":{"tag":"盘后","latestPrice":76.5,"preClose":74.18,"latestTime":"19:30 EST","volume":224,"amount":16939.83,"timestamp":1794961801921,"change":2.32,"changeRate":0.031275,"amplitude":0.031275},"volumeRatio":1.465489,"impliedVol":1.4563,"impliedVolPercentile":0.932},"requestUrl":"/m/hq/s/INBX/wiki","defaultTab":"wiki","newsList":[{"id":"1140714808","title":"Inhibrx Biosciences公布实验性联合抗癌药中期研究数据后,股价重挫22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140714808","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140714808?lang=zh_cn&edition=full","pubTime":"2026-09-08 22:18","pubTimestamp":1788877090,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences股价暴跌22%,缘于该公司披露了其试验性组合癌症药物的中期阶段研究数据。市场对此反应剧烈,股价应声大幅下挫。这家生物科技企业此番公布的数据,源于一项针对该联合疗法疗效和安全性的中段临床试验。投资者在审视这些最新出炉的结果后,显然对前景产生了疑虑,进而引发了抛售潮,拖累股价在交易时段内录得显著跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144527689","title":"Inhibrx Biosciences:INBRX-106围手术期非小细胞肺癌Ⅰ/Ⅱ期临床试验进行中,初步结果预计2027年年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1144527689","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144527689?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:33","pubTimestamp":1788867232,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences正积极推进一项针对INBRX-106的Ⅰ/Ⅱ期临床研究,该试验聚焦于非小细胞肺癌(NSCLC)的围手术期治疗场景,初步数据有望于2027年年中揭晓。\n这家生物制药企业目前正全力投入INBRX-106的早期临床开发,探索其在非小细胞肺癌患者围手术期阶段的应用潜力。按照当前的时间表规划,研究团队期望能在2027年中期获取并公布首批关键性结果。\n颇具看点的是,这项研究不仅标志着INBRX-106临床适应症版图的进一步拓展,也折射出公司在肿瘤免疫治疗细分赛道的战略布局。围手术期策略的引入,意在更早期地介入肿瘤治疗流程,或将为患者带来全新的治疗契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187240423","title":"Inhibrx Biosciences:拟探索Inbrx-106与治疗性癌症疫苗联合应用的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1187240423","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187240423?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:32","pubTimestamp":1788867157,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司今日宣布,其战略布局将延伸至一个新的维度——探索其核心候选药物Inbrx-106与治疗性癌症疫苗的联合使用潜力。此举标志着该公司在肿瘤免疫治疗领域的创新步伐正进一步加快,意图通过多机制协同,开辟更广泛的抗肿瘤治疗路径。Inbrx-106作为该公司研发管线中的关键资产,其与癌症疫苗的潜在组合,不仅有望提升治疗响应率,更可能为当前应答不佳的患者群体带来新的曙光。公司方面对此寄予厚望,认为该联合策略或将在未来的临床开发中占据举足轻重的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179108181","title":"Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中:缓解率近乎翻倍,无进展生存期中位数达9.6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1179108181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179108181?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:31","pubTimestamp":1788867080,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences(INBX)公布了其候选药物INBRX-106在II期头颈鳞状细胞癌(HNSCC)临床研究中的中期数据。结果显示,该药物将缓解率提升近一倍,且无进展生存期(PFS)中位数达到了9.6个月,展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135938113","title":"H.c. Wainwright首次覆盖Inhibrx Biosciences,给予买入评级及245美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1135938113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135938113?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:09","pubTimestamp":1787566149,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences(INBX)近日获得H.c. Wainwright的正式关注。该机构首次覆盖这家生物科技公司,便果断给出“买入”评级,同时将目标股价设定在245美元。这一举动,无疑为市场注入了一剂强心针。245美元的目标价,相较于当前股价,意味着相当可观的潜在上行空间。此举也反映出华尔街对Inhibrx在研管线及技术平台所蕴含价值的初步认可。H.c. Wainwright此次的积极表态,标志着Inhibrx开始进入更多投资者的视野,其后续的研发进展和商业化潜力将成为市场关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134591223","title":"Inhibrx Biosciences二次修订协议带来总计3.25亿美元资金,含1亿美元已到位与2.25亿美元可用额度","url":"https://stock-news.laohu8.com/highlight/detail?id=1134591223","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134591223?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:02","pubTimestamp":1784206950,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司通过其第二次修订协议,成功锁定了高达3.25亿美元的资金支持。该资金安排结构清晰,其中1亿美元已确认获得融资,另有2.25亿美元作为可用额度待后续启用。这一举措显著增强了公司的财务灵活性与研发推进能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188081691","title":"Inhibrx宣布与牛津金融修订贷款协议,总授信额度增至5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188081691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188081691?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206900,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences(INBX)已宣布与牛津金融(Oxford Finance)达成一项修订后的贷款协议。根据新协议,公司获得的总授信额度已扩大至5亿美元。此次修订旨在为公司提供更充足的财务灵活性,以支持其研发管线及运营需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174269329","title":"Inhibrx宣布美国FDA受理Ozekibart用于治疗常规软骨肉瘤患者的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1174269329","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174269329?lang=zh_cn&edition=full","pubTime":"2026-06-15 21:16","pubTimestamp":1781529384,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences(INBX)宣布,其用于治疗常规软骨肉瘤患者的在研药物Ozekibart的生物制品许可申请(BLA)已获得美国食品药品监督管理局(FDA)的受理。FDA的受理标志着该药物审评流程的正式启动,是向潜在获批迈出的关键一步。常规软骨肉瘤是一种罕见的骨癌,目前治疗选择有限,此次BLA的受理为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517645901","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517645901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517645901?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:25","pubTimestamp":1741274709,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时25分,Inhibrx Biosciences, Inc.股票出现异动,股价大幅跳水5.99%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.53%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677324","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677324?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099056,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分,Inhibrx Biosciences, Inc.股票出现波动,股价急速跳水5.01%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.09%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516030626","title":"Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516030626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516030626?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:21","pubTimestamp":1740774085,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时21分,Inhibrx Biosciences, Inc.股票出现波动,股价快速上涨5.52%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.44%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296523","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨12.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296523?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:33","pubTimestamp":1740148429,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时33分,Inhibrx Biosciences, Inc.股票出现波动,股价急速拉升12.34%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.34%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509259695","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509259695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509259695?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:57","pubTimestamp":1738789060,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时57分,Inhibrx Biosciences, Inc.股票出现异动,股价急速上涨5.19%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.97%。其相关个股中,Immatics N V C/Wts 01/07/2025 、Invivyd, Inc.、Transcode Therapeutics, Inc.涨幅较大,Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃,换手率分别为4731.93%、2453.39%、1790.40%,振幅较大的相关个股有Oragenics Inc.、Invivyd, Inc.、Transcode Therapeutics, Inc.,振幅分别为132.24%、108.79%、99.51%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508141018","title":"Inhibrx Biosciences, Inc.盘中异动 急速下挫5.23%报12.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141018","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508141018?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:00","pubTimestamp":1738594837,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时00分,Inhibrx Biosciences, Inc.股票出现异动,股价大幅跳水5.23%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.62%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230037961700f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230037961700f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507621306","title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速上涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507621306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507621306?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:37","pubTimestamp":1738247830,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时37分,Inhibrx Biosciences, Inc.股票出现波动,股价大幅拉升5.77%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.05%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223710abbd4d61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223710abbd4d61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506054503","title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506054503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506054503?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:02","pubTimestamp":1737990134,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时02分,Inhibrx Biosciences, Inc.股票出现异动,股价快速上涨7.41%。截至发稿,该股报14.13美元/股,成交量1.2927万股,换手率0.09%,振幅3.50%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.88%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505040684","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下挫5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505040684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505040684?lang=zh_cn&edition=full","pubTime":"2025-01-24 03:26","pubTimestamp":1737660363,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日03时26分,Inhibrx Biosciences, Inc.股票出现异动,股价快速下跌5.22%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.15%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240326039870ee67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240326039870ee67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505903277","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨5.40%报14.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505903277","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505903277?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:14","pubTimestamp":1737472469,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时14分,Inhibrx Biosciences, Inc.股票出现波动,股价快速拉升5.40%。截至发稿,该股报14.22美元/股,成交量1.2809万股,换手率0.09%,振幅3.97%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.22%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121231429960bc237&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121231429960bc237&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503990758","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨6.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503990758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503990758?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:33","pubTimestamp":1737038019,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时33分,Inhibrx Biosciences, Inc.股票出现异动,股价大幅拉升6.90%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.01%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501162233409606085e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501162233409606085e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503625830","title":"Inhibrx Biosciences, Inc.盘中异动 急速拉升8.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503625830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503625830?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:34","pubTimestamp":1736951665,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时34分,Inhibrx Biosciences, Inc.股票出现波动,股价急速上涨8.08%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.94%。其相关个股中,Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Allovir, Inc.涨幅较大,Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃,换手率分别为186.85%、58.89%、35.75%,振幅较大的相关个股有Onconetix, Inc.、Eterna Therapeutics Inc.、Klotho Neurosciences, Inc.,振幅分别为14.29%、12.79%、12.00%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223425a222ff2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223425a222ff2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":-0.1813},{"period":"1month","weight":-0.1742},{"period":"3month","weight":-0.269},{"period":"6month","weight":-0.3291},{"period":"1year","weight":-0.041},{"period":"ytd","weight":-0.061}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0404},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.0138},{"period":"1year","weight":0.1003},{"period":"ytd","weight":0.0741}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立,是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司,拥有一系列新型候选生物治疗药物,使用其专有的模块化蛋白质工程平台开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.100441},{"month":2,"riseRate":0,"avgChangeRate":-0.118883},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108872},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034815},{"month":5,"riseRate":0.25,"avgChangeRate":-0.039218},{"month":6,"riseRate":0.666667,"avgChangeRate":0.088726},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111417},{"month":8,"riseRate":1,"avgChangeRate":0.030836},{"month":9,"riseRate":0.75,"avgChangeRate":0.016607},{"month":10,"riseRate":0.5,"avgChangeRate":0.197255},{"month":11,"riseRate":0.75,"avgChangeRate":0.223807},{"month":12,"riseRate":0.75,"avgChangeRate":0.232405}],"exchange":"NASDAQ","name":"Inhibrx Biosciences","nameEN":"Inhibrx Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibrx Biosciences,INBX,Inhibrx Biosciences股票,Inhibrx Biosciences股票老虎,Inhibrx Biosciences股票老虎国际,Inhibrx Biosciences行情,Inhibrx Biosciences股票行情,Inhibrx Biosciences股价,Inhibrx Biosciences股市,Inhibrx Biosciences股票价格,Inhibrx Biosciences股票交易,Inhibrx Biosciences股票购买,Inhibrx Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}